The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
本发明涉及11-β羟基类
固醇脱氢酶类型1的
抑制剂、矿物质皮质激素受体(MR)的拮抗剂及其制药组合物。本发明的化合物可用于治疗与11-β羟基类
固醇脱氢酶类型1的表达或活性相关的各种疾病和/或与
醛固酮过多相关的疾病。